期刊
CANCERS
卷 15, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/cancers15112958
关键词
AML; leukemia; NK cell; menin; immunotherapy; cell therapy
类别
Acute Myeloid Leukemia (AML) has a 5-year overall survival rate of 32% from 2012 to 2018, and the number decreases significantly with age and adverse disease risk. This provides opportunities for new drug development and addresses an urgent unmet need. Researchers worldwide are focusing on developing new and existing molecule formulations and combination strategies to improve outcomes in AML patients. This review discusses promising novel agents in different stages of clinical development for AML patients.
Acute Myeloid leukemia (AML) is a clinically heterogeneous disease with a 5-year overall survival of 32% between 2012 to 2018. The above number severely dwindles with age and adverse risk of disease, presenting opportunities for new drug development and is an area of dire unmet need. Basic science and clinical investigators across the world have been working on many new and old molecule formulations and combination strategies to improve outcomes in this disease. In this review, we discuss select promising novel agents in various stages of clinical development for patients with AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据